Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Centrosome Amplification-Targeted Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for STIL drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STIL (STAN Domain) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified for PPI screening. |
View STIL Products |
| Gene Delivery | STIL Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and phenotypic rescue assays. |
View STIL Products |
| Benchmark Ab | Anti-STIL Recombinant Antibody Recombinant positive control for Western Blot, IHC, and Immunofluorescence. |
View STIL Products |
| Validator | STIL siRNA Set For target knockdown verification and specificity profiling. |
View STIL Products |
| Related Target A | PLK4 (Polo-Like Kinase 4) Primary binding partner of STIL; key regulator of centriole duplication. |
View PLK4 Products |
| Related Target B | SASS6 (Spindle Assembly Abnormal Protein 6) Interacts with STIL to form the cartwheel structure of the centriole. |
View SASS6 Products |
| Related Target C | TAL1 (SCL) STIL-TAL1 fusion gene is a major driver in T-cell acute lymphoblastic leukemia (T-ALL). |
View TAL1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intrinsically Disordered Regions (IDRs) in full-length STIL causing aggregation | Truncated functional domains (STAN and Coiled-Coil) optimized for structural stability and monodispersity. |
| High-throughput screening of Protein-Protein Interactions (STIL-PLK4) | Co-validated binding partners (PLK4 PB3 domain) available with matching tag systems (GST/His/Biotin) for robust assay setup. |
| Lack of Controls | Clinical-grade Benchmark Antibodies and validated control plasmids included in the catalog. |
| False Positives in Phenotypic Screens | Sequence-verified siRNA sets included to confirm target-specific centrosome reduction. |
Live STIL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for STIL therapeutics is intensifying, with major players shifting focus from traditional cytotoxic agents to targeted disruption of the centrosome duplication cycle. As first-generation PLK4 inhibitors face therapeutic window limitations due to systemic toxicity, the next wave of R&D is targeting the specific protein-protein interaction (PPI) interface between STIL and PLK4 or STIL and SASS6 to achieve tumor-selective synthetic lethality.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Biotech Startups | Breast Cancer, Pancreatic Cancer, Ovarian Cancer | High-purity STAN Domain Recombinant Protein for FP/SPR screening. |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Solid Tumors with Centrosome Amplification | Lentivirus for stable cell lines to monitor endogenous STIL degradation kinetics. |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | T-Cell Acute Lymphoblastic Leukemia (T-ALL) | Validated siRNA sets for transfection optimization and target knock-down confirmation. |